First 10 runs free
    Intelligence Feed event · Equity · 2026-11-08

    Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand

    Question

    Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand

    Direct answer

    The Motley Fool reports that Eli Lilly raised full-year 2026 revenue guidance to between $91 billion and $92 billion, up from $85 billion to $87 billion previously. The $5.5 billion upward revision reflects accelerating global demand for its GLP-1 portfolio, led by Mounjaro and Zepbound. The stock has advanced 57% year-to-date, stretching its valuation multiple to 47x trailing earnings. Market participants continue to evaluate whether sustained volume growth in metabolic therapeutics can defend this premium multiple against broader sector valuation compression.

    Original publisher
    Market Ontology
    Evidence through
    2026-11-08
    Published
    2026-11-08
    Revision
    1 · 2026-11-08

    Cite as: Market Ontology, “Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand”, revision 1, evidence through 2026-11-08. https://marketontology.com/market-events/2026-11-08/eli-lilly-raises-2026-revenue-guidance-to-91b-92b-driven-by-glp-1-demand-b86abc

    EQUITY
    Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand
    The Motley Fool reports that Eli Lilly raised full-year 2026 revenue guidance to between $91 billion and $92 billion, up from $85 billion to $87 billion previously. The $5.5 billion upward revision reflects accelerating global demand for its GLP-1 portfolio, led by Mounjaro and Zepbound. The stock has advanced 57% year-to-date, stretching its valuation multiple to 47x trailing earnings. Market participants continue to evaluate whether sustained volume growth in metabolic therapeutics can defend this premium multiple against broader sector valuation compression.
    LLYNVO
    Impact
    79
    YESTERDAY
    SIG
    85%
    LLYNVO
    Eli Lilly Raises 2026 Revenue Guidance to $91B-$92B Driven by GLP-1 Demand
    The Motley Fool reports that Eli Lilly raised full-year 2026 revenue guidance to between $91 billion and $92 billion, up from $85 billion to $87 billion previously. The $5.5 billion upward revision reflects accelerating global demand for its GLP-1 portfolio, led by Mounjaro and Zepbound. The stock has advanced 57% year-to-date, stretching its valuation multiple to 47x trailing earnings. Market participants continue to evaluate whether sustained volume growth in metabolic therapeutics can defend this premium multiple against broader sector valuation compression.
    → A $5.5B upward revision in 2026 top-line guidance supports LLY's 47x forward P/E multiple against biopharma sector multiple compression.
    Impact
    The Motley Fool reports that Eli Lilly raised full-year 2026 revenue guidance to between $91 billion and $92 billion, up from $85 billion to $87 billion previously. The $5.5 billion upward revision reflects accelerating global demand for its GLP-1 portfolio, led by Mounjaro and Zepbound. The stock has advanced 57% year-to-date, stretching its valuation multiple to 47x trailing earnings. Market participants continue to evaluate whether sustained volume growth in metabolic therapeutics can defend this premium multiple against broader sector valuation compression.
    Affected
    LLYNVO
    Transmission
    A $5.5B upward revision in 2026 top-line guidance supports LLY's 47x forward P/E multiple against biopharma sector multiple compression.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LLYforward revenue guidance upgrade to $91B-$92BUp1-4wSource reports Eli Lilly raised 2026 revenue guidance to $91-92 billion from $85-87 billion.
    NVOtherapeutic class TAM expansionUp1-4wEli Lilly's $5.5B upward guidance revision affirms aggregate demand for GLP-1 therapeutics.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards